Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.

5 Feb 2010

Majority of rural hospital stays are covered by Medicare

Medicare patients accounted for almost half of all stays (45 percent) at rural hospitals in 2007, while the percentage of Medicare beneficiaries who were admitted to urban hospitals was considerably lower (35 percent) , according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

5 Feb 2010

Texas Health Dallas offers heart and vascular screening program for women

When Mary Gill went to bed that night, nothing would have made anyone think heart disease — not even Mary. She was thin and 42 years old. She exercised regularly, ate a healthy diet and never smoked.

4 Feb 2010

Ontario's doctors urge patients to make simple lifestyle changes for better health

The number of patients living with chronic disease in Ontario is on the rise, finds a new report by the Ontario Medical Association (OMA). The study reveals that between 1995-2005, the number of patients with diabetes has increased over 50% and more concerning is that the number of patients with diabetes aged 19 and younger has gone up by 20%.

4 Feb 2010

New technique may reduce recovery time in arrhythmia patients

A surgeon and an electrophysiologist in the Methodist DeBakey Heart & Vascular Center last week worked together to perform a novel, minimally-invasive procedure to treat a common but dangerous arrhythmia in a 61-year-old lawyer from east Texas who has suffered from the condition for months.

4 Feb 2010

Geisinger Health System and TGen sign research agreement

Geisinger Health System and the Translational Genomics Research Institute today announced the signing of a strategic research agreement that provides a focused look at the gaps in clinical medicine where biomedical research can make a difference.

4 Feb 2010

TGen, Geisinger Health System sign strategic research agreement

The Translational Genomics Research Institute (TGen) and Geisinger Health System today announced the signing of a strategic research agreement that provides for a focused look at the gaps in clinical medicine where biomedical research can make a difference.

4 Feb 2010

Innovative discharge program reduces congestive heart failure readmissions

An innovative discharge program developed by Saddleback Memorial Medical Center combining coordination of hospital and community resources, strong patient education and the IDEAL LIFE Bluetooth-enabled wireless remote health monitoring system has helped to reduce congestive heart failure (CHF) readmissions by 50 percent

3 Feb 2010

Response Biomedical continues global market expansion, signs Guangzhou Wondfo Biotech in China

Response Biomedical Corporation announced that the Company has signed a second partner, Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) in China to sell the Company’s diagnostic products, expanding its strategic presence in this important global market.

2 Feb 2010

ZOLL Medical's LifeVest Wearable Defibrillator named one of top five innovative medical devices of 2009

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that the Medical Device Network has named the LifeVest® Wearable Defibrillator as one of the five most innovative and life-changing medical devices of 2009.

28 Jan 2010

Study shows benefits of endoscopic sinus surgery for patients with chronic sinusitis

Adults with chronic rhinosinusitis -a debilitating inflammation of the nasal passages that lasts for months and keeps coming back - report significantly improved quality of life following minimally invasive endoscopic sinus surgery, according to a new study led by Oregon Health & Science University (OHSU).

28 Jan 2010

Pfizer reports final results from randomized Phase 3 trial of Sutent

Pfizer Inc. today announced final results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic neuroendocrine tumors, a type of cancer which originates in the hormone-producing area of the pancreas.

23 Jan 2010

FDA approves continuous-flow heart-assist device pioneered at Texas Heart Institute at SLEH

The federal Food and Drug Administration today approved a continuous-flow heart-assist device pioneered at the Texas Heart Institute (THI) at St. Luke’s Episcopal Hospital (SLEH) for use as a permanent treatment for advanced heart failure.

21 Jan 2010

Erectile dysfunction can be strongly related to the development of CVD

In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).

20 Jan 2010

Health Policy Research Roundup: New Orleans clinic experiences, health reform and lagging biomedical research funds

Journal of the American Medical Association: Funding of US Biomedical Research, 2003-2008 - After doubling in a decade, the rate of increase in biomedical research in the U.S. has slowed since 2005, and the level of funding from the National Institutes of Health and industry appears to have decreased by 2 percent in 2008, after adjusting for inflation, the authors of this study report.

18 Jan 2010

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene® I.V. (nicardipine hydrochloride) is significantly more effective than intravenous labetalol for the management of blood pressure (BP) in stroke patients.

12 Jan 2010

Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced

VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.

7 Jan 2010

EPO grants notice of allowance for Response Biomedical’s ‘Fong Patent’

Response Biomedical Corporation announced today that the Company has received a Notice of Allowance from the European Patent Office for the patent entitled “Sensitive Immunochromatographic Assay”, referred to as the “Fong Patent”.

7 Jan 2010

Bioheart signs distribution agreements to market Home Heart Failure Monitoring Systems in U.S.

Bioheart, Inc. announced today that the company has signed distribution agreements with Restoration Medical, McRay Medical, Alamo Scientific and Morey Medical. These distributors will assist Bioheart with introducing its Home Heart Failure Monitoring Systems to physicians and hospitals throughout the United States.

6 Jan 2010

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx’s novel anticoagulant agent, tecarfarin (ATI-5923).

5 Jan 2010

Congestive Heart Failure News and Research

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Majority of rural hospital stays are covered by Medicare

Texas Health Dallas offers heart and vascular screening program for women

Ontario's doctors urge patients to make simple lifestyle changes for better health

New technique may reduce recovery time in arrhythmia patients

Geisinger Health System and TGen sign research agreement

TGen, Geisinger Health System sign strategic research agreement

Innovative discharge program reduces congestive heart failure readmissions

Response Biomedical continues global market expansion, signs Guangzhou Wondfo Biotech in China

ZOLL Medical's LifeVest Wearable Defibrillator named one of top five innovative medical devices of 2009

Study shows benefits of endoscopic sinus surgery for patients with chronic sinusitis

Pfizer reports final results from randomized Phase 3 trial of Sutent

FDA approves continuous-flow heart-assist device pioneered at Texas Heart Institute at SLEH

Erectile dysfunction can be strongly related to the development of CVD

Health Policy Research Roundup: New Orleans clinic experiences, health reform and lagging biomedical research funds

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced

EPO grants notice of allowance for Response Biomedical’s ‘Fong Patent’

Bioheart signs distribution agreements to market Home Heart Failure Monitoring Systems in U.S.

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News